Puma Biotechnology Current Ratio 2008-2021 | PBYI

Puma Biotechnology current ratio from 2008 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Puma Biotechnology Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.17B $0.14B 1.22
2021-03-31 $0.16B $0.14B 1.17
2020-12-31 $0.15B $0.11B 1.28
2020-09-30 $0.16B $0.12B 1.35
2020-06-30 $0.16B $0.10B 1.68
2020-03-31 $0.16B $0.09B 1.75
2019-12-31 $0.17B $0.09B 1.83
2019-09-30 $0.15B $0.09B 1.71
2019-06-30 $0.16B $0.09B 1.72
2019-03-31 $0.26B $0.10B 2.53
2018-12-31 $0.20B $0.07B 3.03
2018-09-30 $0.17B $0.06B 3.01
2018-06-30 $0.17B $0.06B 2.68
2018-03-31 $0.11B $0.06B 1.91
2017-12-31 $0.11B $0.06B 1.82
2017-09-30 $0.12B $0.10B 1.23
2017-06-30 $0.16B $0.05B 3.40
2017-03-31 $0.21B $0.04B 4.68
2016-12-31 $0.24B $0.04B 6.31
2016-09-30 $0.12B $0.04B 3.12
2016-06-30 $0.15B $0.04B 3.95
2016-03-31 $0.19B $0.04B 4.87
2015-12-31 $0.22B $0.03B 6.89
2015-09-30 $0.26B $0.03B 10.05
2015-06-30 $0.29B $0.03B 11.03
2015-03-31 $0.32B $0.03B 12.14
2014-12-31 $0.15B $0.04B 3.36
2014-09-30 $0.16B $0.03B 5.45
2014-06-30 $0.18B $0.03B 6.57
2014-03-31 $0.21B $0.02B 10.46
2013-12-31 $0.10B $0.02B 5.00
2013-09-30 $0.11B $0.02B 5.75
2013-06-30 $0.12B $0.02B 6.23
2013-03-31 $0.14B $0.02B 6.39
2012-12-31 $0.15B $0.02B 6.87
2012-09-30 $0.03B $0.03B 1.28
2012-06-30 $0.04B $0.02B 2.69
2012-03-31 $0.05B $0.01B 5.35
2011-12-31 $0.05B $0.00B 91.42
2011-09-30 $0.00B $0.00B 0.12
2011-06-30 $0.00B $0.00B 0.52
2011-03-31 $0.00B $0.00B 0.08
2010-12-31 $0.00B 0.00
2010-09-30 $0.00B 0.00
2010-06-30 $0.00B 0.00
2010-03-31 $0.00B 0.00
2009-12-31 $0.00B $0.00B 1.04
2009-09-30 $0.00B 0.00
2009-06-30 $0.00B $0.00B 1.04
2009-03-31 $0.00B $0.00B 0.20
2008-12-31 $0.00B $0.00B 0.05
2008-09-30 $0.00B $0.00B 0.05
2008-06-30 $0.00B $0.00B 4.60
2008-03-31 $0.00B 0.00
2007-12-31 $0.00B 0.00
2007-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.218B $0.225B
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86